Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy

Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.

The objective of this study is to determine the acute and chronic [4-week] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.

Visão geral do estudo

Descrição detalhada

This study involves fasted and post-prandial components.

Fasted Study:

Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.

There will be a 4-week washout period during the two Treatment Periods.

Post-prandial study:

Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

36

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Ontario
      • Guelph, Ontario, Canadá, N1G 0B4
        • Nutrasource Diagnostics Inc.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Be an adult between the ages of 18 and 70;
  • Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
  • Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
  • Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
  • Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
  • Have a Body Mass Index (BMI) less than 35.0
  • Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.

Exclusion Criteria:

  • Be younger than 18 years of age or older than 70 years of age;
  • Be an adult pre- or peri-menopausal female;
  • Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
  • Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
  • Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
  • Have high blood pressure [greater than 140/100]
  • Have a Body Mass Index (BMI) equal to or greater than 35.0
  • Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
  • Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
  • Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
  • Consume more than two (2) fish meals on a weekly basis
  • Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
  • Anticipate or have planned surgery during the course of the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: 1 (Dietary Supplement - Fish Oil)

On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.

On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol.

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
Experimental: 2 (Placebo)

On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.

On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol.

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Triglyceride [TG]
Prazo: 0 and 4 weeks
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
0 and 4 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Glucose
Prazo: 0 and 4 weeks
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
0 and 4 weeks
Insulin
Prazo: 0 and 4 weeks
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
0 and 4 weeks
Total cholesterol [TC]
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
High-density lipoprotein [HDL]
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Low-density lipoprotein [LDL]
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Very low-density lipoprotein [VLDL]
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Lipoprotein A
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Intermediate-density lipoprotein [IDL]
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Remnant Lipoproteins
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
High-sensitivity C-Reactive Protein [hs-CRP]
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Homocysteine
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Essential Fatty Acid Profile
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Apolipoprotein B
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Apolipoprotein A-1
Prazo: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Alison Duncan, Ph.D., R.D., University of Guelph

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de setembro de 2012

Conclusão Primária (Real)

1 de dezembro de 2013

Conclusão do estudo (Real)

1 de fevereiro de 2014

Datas de inscrição no estudo

Enviado pela primeira vez

10 de setembro de 2012

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de setembro de 2012

Primeira postagem (Estimativa)

21 de setembro de 2012

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

7 de fevereiro de 2014

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de fevereiro de 2014

Última verificação

1 de fevereiro de 2014

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever